The trial and error approach to epilepsy treatment has not changed for over a century but machine learning and patient derived stem cells promise a personalised and more effective strategy, argue Patrick Kwan and colleagues E pilepsy affects 50 million people worldwide with no age, ethnic, or geographical boundary. 1 Patients have recurrent seizures that can lead to injuries, cognitive decline, psychosocial dysfunction, and even death. Epilepsy is caused by brain insults such as trauma, stroke, tumour, inflammation, and infection as well as systemic changes resulting from genomic variation. Patients with epilepsy have increased comorbidities, including cerebrovascular, neurocognitive, and psychiatric diseases. 2 Better epilepsy control will therefore improve overall brain health.